I think you have touched on a reason more PR's have not been issued. The former CRO did tremendous damage and caused a great loss of time. The new CRO is gleaning through the garbage data, looking for some nuggets of value to the FDA and medical community at large. Of course, the research team is conducting additional trials to enhance the pipeline.

Statements like the one you quoted resulted in a "D" for my Experimental Psychology class. I hated attending class and my performance, and subsequent grade reflected that. That "D" was generous, BTW.

IMO, management is afraid to release information prematurely. The taint of vague PR's, intended to promote clicks and eyeballs, and a quick spike in share price continues to haunt Cytodyn. Dr. Jay and the team are being rigorous, perhaps to a fault to we stakeholders. However, failure to exercise rigor could result in the death of the company.